Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.
LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes; also referred to as TNFSF14) is an immunoregulatory cytokine. LIGHT and its signaling receptors, HVEM (TNFRSF14), and lymphotoxin β receptor (TNFRSF3), form an immune regulatory network with two co-receptors of herpesvirus entry mediator, checkpoint inhibitor B and T Lymphocyte Attenuator (BTLA), and CD160 (the LIGHT-signaling network). Accumulating evidence points to the dysregulation of the LIGHT-signaling network as a disease-driving mechanism in autoimmune and inflammatory reactions in barrier organs. Therefore, we believe reducing LIGHT levels can moderate immune dysregulation in many acute and chronic inflammatory disorders.
Oppenheimer's 33rd Annual Healthcare Conference PresentationView This Presentation
Cerecor | AEVI Merger Details
Please see the attached to documents for detailed information regarding the Aevi acquisition / merger and or a simple question and answer document
|CERECOR SEC S4 Aevi Acquisition||Download|
|CERECOR Q&A Document||Download|
Avalo Therapeutics, Inc.
1500 Liberty Ridge Drive
Wayne, PA 19087